Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction chemoradiotherapy for head and neck squamous cell carcinoma (iCHRTL)
2024-517480-23-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoints: Objective response rate after induction assessment (ORR), Local and nodal healing rate assessment (LRC) and 3 more. Planned start Dec 2024; status: authorised.
02
Drugs
carboplatinpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-517480-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517480-23-00.